What this injection does inside the knee

Most patients arriving at this page want a straight answer: what will I actually feel in the days after a Liquid Cartilage injection in my knee? The answer depends on understanding what the treatment puts into your joint — and that takes only a paragraph.

Liquid Cartilage™ is the clinical name used at certain UK private clinics for ChondroFiller™, an injectable collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany. It is a CE-marked Class III medical device — not FDA-approved and not funded by the NHS — delivered during an outpatient appointment under ultrasound guidance, with no incisions or theatre admission involved.

Once the liquid collagen reaches the cartilage defect, it self-gels within three to five minutes and creates a three-dimensional scaffold inside the joint. This triggers a process called acellular matrix-induced chondrogenesis: the scaffold draws the patient's own progenitor cells from the surrounding tissue, which gradually populate it and replace it with hyaline-like repair tissue over the following months. The injection does not implant cartilage directly.

Because the body is responding to a new intra-articular scaffold — not to a surgical wound — the side-effect pattern that follows is distinctive, and largely predictable.

Side effects most patients notice in the first 72 hours

Three responses are consistently reported in the first two to three days, and all three are normal.

Localised swelling is the most common and tends to peak around 24 hours after the injection. It reflects the knee joint accommodating the collagen scaffold as it gels — a physiological response, not a sign of a problem. Most patients describe it as a sense of fullness rather than gross visible swelling.

A deep, pressure-like ache accompanies the swelling. The key word here is pressure: this dull discomfort is distinctly different from sharp surgical pain, and its presence does not indicate the injection has failed or caused harm. It arises from the scaffold settling into the defect and the surrounding tissue responding.

Joint stiffness is the third element of the triad, often most noticeable first thing in the morning or after sitting for a prolonged period.

All three typically resolve within 48–72 hours without specific treatment. Practical self-care in this window:

• Rest the leg and avoid high-impact activities — running, jumping, vigorous sport — for the first 24–48 hours to allow the scaffold to stabilise
• Apply ice wrapped in a cloth for short periods to reduce swelling
• Keep the leg elevated when resting
• Take mild over-the-counter analgesia if needed
• Light walking from the outset is safe and generally encouraged

The expected trajectory is improvement from around the 24-hour mark. If symptoms worsen rather than ease beyond 72 hours, that directional change — not the symptoms themselves — is what warrants attention, as the next section explains.

Risks worth knowing — and when to contact the clinic

Direction matters more than intensity when assessing recovery. Swelling, ache, and stiffness are expected — but all three should be moving toward resolution by the 24-hour mark. When symptoms worsen rather than ease, that trajectory is the clinical signal.

Infection is the most important risk to recognise. Any intra-articular knee injection carries a small procedural risk of introducing infection, irrespective of the material used. Warning signs are specific: swelling that continues to increase beyond 72 hours, deepening rather than easing pain, spreading redness around the joint, persistent warmth, or fever. Any of these warrants same-day contact with the treating clinic — not watchful waiting.

Allergic reaction to the murine-derived (rat-sourced) Type I collagen is a contraindication risk, which is why a sensitivity history is taken before treatment is offered. Available published sources do not quantify how often a reaction occurs in the broader treated population; the frequency is simply unknown from available data rather than established as negligible.

Fibrous tissue formation has been linked specifically to technical overfilling of the cartilage defect, not to the collagen material itself. The Demmer (2025) prospective study found that flush-fill applications were entirely free of fibrous tissue formation — identifying this as a precision-of-technique issue rather than an inherent device risk.

Non-gelation — the scaffold failing to set inside the defect — is the most frequently logged technical event at approximately 0.01% of cases. It is a procedural outcome rather than a patient-harm event.

Patients this injection is not suitable for

Not everyone with knee cartilage damage is a candidate for this treatment. The following groups are excluded, and understanding why helps clarify who the procedure is designed for.

• Known allergy to murine (mouse-derived) collagen. Because ChondroFiller™ is composed of Type I collagen sourced from rodents, a confirmed sensitivity is an absolute contraindication. This is why a detailed allergy history is taken before treatment is considered.
• Kellgren-Lawrence Grade IV osteoarthritis (bone-on-bone OA). The scaffold is designed to fill focal, bounded cartilage defects in a joint where the surrounding cartilage is structurally intact. In end-stage diffuse OA, where cartilage loss is extensive and the joint architecture is compromised, the biological and mechanical conditions for scaffold integration are not present.
• Active infection — joint or systemic. Introducing any intra-articular material into an infected environment carries significant risk of seeding or worsening the infection. Treatment is deferred until infection is fully resolved.
• Coagulation disorders or anticoagulant therapy that cannot be safely managed around the procedure. Uncontrolled bleeding risk is a contraindication; this is reviewed on an individual basis with the treating clinician.
• Pregnancy or breastfeeding.

This list also explains something important about the safety data discussed earlier. The post-market surveillance figure of zero serious adverse device effects across more than 19,000 cases reflects outcomes in carefully screened patients — those with focal Grade III or IV cartilage defects and healthy surrounding cartilage borders. That record does not automatically extend to patients outside this profile.

Self-screening against this list is a useful starting point, but confirming eligibility requires a clinical assessment. A consultation is the appropriate place to establish suitability, review imaging, and discuss whether this pathway is the right fit.

What the post-market safety record actually shows

The headline figure from Meidrix Biomedicals GmbH's post-market programme is striking: across more than 19,000 treated cases since 2013, not a single serious adverse device effect has been recorded. The overall complaint rate sits at approximately 0.06% — among the lowest logged for any cartilage-repair intervention.

Context makes that figure more meaningful. The injectable pathway carries a reoperation rate of 3–8%, compared with up to 41% for microfracture and up to 37% for ACI or MACI procedures. These are different types of procedure, but the benchmark matters for patients weighing options: a lower-risk outpatient injection against theatre-based surgical repair.

MRI data from European studies adds objective confirmation that the collagen scaffold is not provoking a harmful tissue response. Post-treatment imaging shows reduction in bone marrow oedema, diminished joint effusion, and progressive defect fill — MOCART scores of 81–84 at one year indicate more than 80% structural integration. Functional improvement, measured by IKDC scores, averages roughly 30 points above baseline and holds at three years.

One caveat deserves plain statement. Every figure cited here originates from manufacturer-sponsored post-market clinical follow-up, principally Meidrix Biomedicals GmbH's own surveillance programme. No independent blinded randomised controlled trial has been conducted specifically for the ultrasound-guided injectable knee form. That does not invalidate a dataset of 19,000 cases, but an independent evidence base confirming these findings does not yet exist.

Recovery after the injection and what to expect next

Recovery follows a broadly predictable arc, though the pace varies between individuals.

Weeks 1–6 — protecting the scaffold. The collagen gel needs time to stabilise and begin recruiting the patient's own repair cells. The focus is on keeping the joint moving without heavy loading: sustained impact, twisting under weight, and repetitive stress should wait. (Immediate self-care — rest, ice, and activity limits — is covered in the earlier section on side effects, and those recommendations remain relevant throughout this phase.)

Weeks 6–12 — progressive strengthening. As the scaffold integrates, physiotherapy introduces work to restore muscle strength and joint stability. Low-impact exercise begins in this window, and most patients start to notice meaningful symptom improvement.

Three months to one year — gradual return to activity. Higher-impact movement and sport are reintroduced cautiously, guided by clinical review and symptom response. MRI changes — reduced bone marrow oedema, improved defect fill, and visible joint-space widening — are typically detectable from around three months, though full tissue maturation continues to twelve months. Outcomes depend on defect size, age, and overall joint health; a pre-injection consultation should address these variables honestly, since 70–85% of appropriately selected patients achieve meaningful relief but individual prognosis is not uniform.

For patients for whom this article raises relevant questions, Lincolnshire Knee — part of the MSK Doctors group — accepts assessments without a GP referral. Details are at lincolnshireknee.co.uk.